Homocysteine: An aetiological contributor to peripheral vascular arterial disease

ANZ Journal of Surgery

Volumn 72, Issue 9, 2002, Pages 668-671

  Kuan, Yew Ming ^a   Dear, Anthony E ^a   Grigg, Michael J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Folate; Homocysteine; Methionine; Supplementation; Vitamin B12; Vitamin B6

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

AMINO ACID ANALYSIS; AMINO ACID METABOLISM; BLOOD COMPONENT; CENTRIFUGATION; DIETARY INTAKE; DISEASE SEVERITY; ENZYME DEFICIENCY; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNOASSAY; METHYLATION; MOLECULAR BIOLOGY; PERIPHERAL VASCULAR DISEASE; REVIEW; SAMPLING; VASCULARIZATION;

HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; PERIPHERAL VASCULAR DISEASES;

EID: 0036378392     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-2197.2002.02509.x     Document Type: Review

References (34)

1. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 1969; 56: 111-28.
2. Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-81.
3. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407-13.
4. Eikelboom JW, Lonn E, Genest Jr J, Hankey G, Yusuf S. Homocysteine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann. Intern. Med. 1999; 131: 363-75
5. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
6. Shipchandler MT, Moore EG. Rapid, fully automated measurement of plasma homocysteine with the Abbott IMx analyzer. Clin. Chem. 1995; 41: 991-4.
7. Frantzen F, Faaren AL, Alfheim I, Nordhei AK. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin. Chem. 1998; 44: 311-16.
8. Donnelly JG, Pronovost C. Evaluation of the Abbott IMx fluorescence polarization immunoassay and the bio-rad enzyme immunoassay for homocysteine: Comparison with high-performance liquid chromatography. Ann. Clin. Biochem. 2000; 37: 194-8
9. Blanco-Vaca F, Arcelus R, Gonzalez-Sastre F, Ordonez-Llanos J, Queralto-Compano JM. Comparison of the Abbott IMx and a high-performance liquid chromatography method for measuring total plasma homocysteine. Clin. Chem. Lab. Med. 2000; 38: 327-9.
10. Marangon K, O'Byrne D, Devaraj Jialal I. Validation of an immunoassay for measurement of plasma total homocysteine. Am. J. Clin. Pathol. 1999; 112: 757-62.
11. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ 1998; 316: 894-8.
12. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Ann. Rev. Med. 1988; 49: 31-62
13. Langman LJ, Cole DEC. Homocysteine. Crit. Rev. Clin. Lab. Sci. 1999; 36: 365-406.
14. Langman LJ, Cole DEC. Homocysteine: Cholesterol of the 90s? Clin. Chim. Acta 1999; 286: 63-80.
15. Linnebank M, Homberger A, Junker R, Nowak-Goettl U, Harms E, Koch HG. High prevalence of the 1278T mutation of the human cystathionine B-synthase detected by a novel screening application. Thromb. Haemost. 2001; 85: 986-8.
16. Clarke R, Daly L, Robinson K et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N. Engl. J. Med. 1991; 324: 1149-55.
17. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala677 to Val in the methylene tetrahydrofolate reductase gene: A risk factor for arterial disease and venous thrombosis. Thromb. Haem. 1997; 77: 818-21.
18. Rozen R. Genetic predisposition to hyperhomocysteinemia: Deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb. Haem. 1997; 78: 523-6.
19. Shaw JT, McWhinney B, Tate JR et al. Plasma homocysteine levels in indigenous Australians. Med. J. Aust. 1999; 170: 19-22
20. De Jong SC, Stehouwer CDA, Van Der Berg M, Geurts TW, Bouter LM, Rauwerda JA. Normohomocysteinaemia and vitamin treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study. J. Int. Med. 1999; 246: 87-96.
21. Taylor LM, Moneta GL, Sexton GJ, Schuff RA, Porter JM Homocysteine and Progression of Atherosclerosis Study Investigators. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J. Vasc. Surg. 1999; 29: 8-21.
22. Boers GHJ. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb. Haem. 1997; 78: 520-2.
23. Oliver MF. Serum cholesterol - The knave of hearts and the joker. Lancet 1981; 2: 1090-5.
24. Rose G, Hamilton PJS, Keen H, Reid DD, McCartney P, Jarrett RJ. Myocardial ischaemia, risk factors and death from coronary heart disease. Lancet 1977; 1: 105-9.
25. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA 1986; 256: 2823-8
26. Currie IC, Wilson YG, Scott J et al. Homocysteine: An independent risk factor for the failure of vascular intervention. Br. J. Surg. 1996; 83: 1238-41.
27. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: Cause or effect? Am. J. Clin. Nutr. 2000; 72: 315-23.
28. Grobe H. Homocystinuria (cystathionine synthase deficiency). Results of treatment in late-diagnosed patients. Eur J. Pediatr. 1980; 135: 199-203.
29. Yap S, Naughten ER, Wilcken B, Wilcken DE, Boers GH. Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: Effects of homocysteine-lowering therapy. Semin. Thromb. Hemost. 2000; 26: 335-40.
30. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am. J. Clin. Nutr. 2000; 72: 324-32.
31. Wilcken DE, Wilcken B. B vitamins and homocysteine in cardiovascular disease and aging. Ann. N. Y. Acad. Sci. 1998; 854: 361-70.
32. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995; 346: 85-9.
33. Ubbink JB, Becker PJ, Hayward Vermaak WJ, Delport R. Results of B vitamin supplementation study used in a prediction model to define reference range for plasma homocysteine. Clin. Chem. 1995; 41: 1033-7.
34. Savage DG, Lindenbaum J. Folate-cobalamin interactions. In: Bailey LB (ed.) Folate in Health and Disease. New York: Marcel Dekker, 1995; 237-85.